|Articles|February 28, 2017

Nexera XR

Tried and trusted all-rounder

A true multi-talent, the Nexera XR ultra high performance liquid chromatograph has become an indispensable tool in laboratories of versatile industries, such as pharmaceuticals, biochemistry, chemistry, environmental and foods. Users benefit from high-speed, high-resolution analysis without compromising robustness or reliability.

 

The Nexera XR modular UHPLC system bridges the gap between the flexibility clients need and the reliability they want. The wide range of highly accurate and reliable modules provides the optimum system for analytical challenges in any field.

 

On the safe side – with a pressure resistance of 660 bar, the Nexera XR is a reliable all-round system, providing the superior performance of UHPLC with the robustness of a conventional HPLC system.

 

The flexible choice – modular design allows configuration of tailor-made systems to meet specific application requirements. Each module delivers outstanding, reliable performance from HPLC to UHPLC application.

 

The sensible option – the SPD-30AM multi-wavelength detector and RF-20Axs fluorescence detector offer unmatched performance. Equipped with unequalled optics and temperature control, these detectors achieve excellent sensitivity, baseline stability and reproducibility.

 

For more information please visit: www.shimadzu.eu

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.